跳至主要内容
临床试验/NCT04593108
NCT04593108Unknown不适用

Study at Zagazig General Hospital

Dr.Dalia Mohammed Al Sayed Zaki1 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2019年1月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
320
试验地点
1
主要终点
Complete abortion

研究概览

简要总结

Aim of study Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester.

Hypothesis:

Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester.

Research question:

Will letrozole- misoprostol protocol give better results than misoprostol- alone protocol in induction of abortion during the first trimester?

详细描述

Aim of the Work

Compare the success rate of misoprostol with versus without letrozole as a pretreatment for medical termination of pregnancy during the first trimester.

Hypothesis:

Letrozole value as a pre-treatment medication for misoprostol in induction of abortion during the first trimester.

Research question:

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Woman age more than 18 years old (age of legal consent).
  • BMI ranges between 25 kg/m2 and 35 kg/m
  • Gestational age of 63 days' gestation (or less).
  • Missed abortion.
  • Hemoglobin leve
  • Exclusion criteria:
  • Woman age less than 18 years old.
  • BMI less than 25 kg/m2 or more than 35 kg/m
  • Gestational age more than 63 days' gestation.
  • Molar pregnancy.
  • Hemoglobin level less than 10 gm/dL.
  • Fibroid uterus.
  • Uterus with congenital anomalies.
  • Previous attempts for induction of abortion in the current pregnancy.
  • Coagulation defect i.e. coagulopathy.
  • Contraindication for induction of abortion e.g. heart failure.
  • Allergy to misoprostol or letrozole.

排除标准

  • 未提供

研究组 & 干预措施

Letrozole misoprostol

Group (A):

A participant will receive three tablets of letrozole (Letrozole®, Technopharma) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start

干预措施: Letrozole misoprostol (Device)

Misoprostol,placebo

Group (B):

A participant will receive three tablets of placebo as a single dose on day One, then she took the second dose herself on day Two and will be told to bring back the empty pack. The third dose will be given on admission to hospital on day Three followed by 4 tablets of vaginal misoprostol (200 μg) (Cytotec®, Pfizer) soaked with saline every three hours for maximum two doses.then give antibiotics when abortion start

干预措施: Misoprostol, placebo (Drug)

结局指标

主要结局

Complete abortion

时间窗: 1week

Complete abortion (complete expulsion of products of conception with no need for curettage) within one week from the first dose of misoprostol.

次要结局

未报告次要终点

研究者

发起方
Dr.Dalia Mohammed Al Sayed Zaki
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Dr.Dalia Mohammed Al Sayed Zaki

Banha university

Benha University

研究点 (1)

Loading locations...

相似试验